Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Fields

Vascular Neurology Portland, OR Medical Doctor

NPI 1366577983 CMS profile 243097

3181 Sw Sam Jackson Park Rd # L-226, Ohsu Neurosciences Critical Care, Portland, OR 97239

Open in the dashboard

General payments

$165,116

351 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Fields of Portland, OR is reported in the CMS Open Payments database as having received $165,116 across 351 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Vascular Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $58,734 99
2024 General $19,338 52
2023 General $28,506 43
2022 General $31,643 76
2021 General $18,003 42
2020 General $6,482 14
2019 General $2,410 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Fields
  • Vascular Neurology median
  • Middle half of Vascular Neurology
  • National median

In program year 2025, general payments to Jeremy Fields were reported at $58,734. Among 416 Vascular Neurology profiles paid that year, the median was $360 and the middle half received between $91 and $1,472.

Show as a table
Year Jeremy Fields Vascular Neurology median Middle half National median
2019 $2,410 $263 $102–$1,640 $163
2020 $6,482 $153 $45–$1,000 $114
2021 $18,003 $261 $100–$1,355 $132
2022 $31,643 $242 $87–$1,273 $149
2023 $28,506 $322 $97–$1,266 $160
2024 $19,338 $247 $70–$1,053 $164
2025 $58,734 $360 $91–$1,472 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. MicroVention, Inc. $129,632 153 payments
  2. Route 92 Medical, Inc. $17,810 5 payments
  3. Medtronic, Inc. $9,871 32 payments
  4. Stryker Corporation $5,450 129 payments
  5. Balt USA, LLC $1,505 3 payments
  6. Penumbra, Inc. $296 18 payments
  7. Medtronic USA, Inc. $270 6 payments
  8. Silk Road Medical, Inc. $152 1 payment
  9. Imperative Care, INc $51 1 payment
  10. Edwards Lifesciences Corporation $49 1 payment
  11. Other $31 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $116,890 72 payments
  2. Consulting Fee $19,355 3 payments
  3. Travel and Lodging $18,992 55 payments
  4. Food and Beverage $9,879 221 payments
Products named General payments · program years 2019–2025
  1. WEB ANEURYSM EMBOLIZATION SYSTEM Neurological Product $112,739 121 payments
  2. Pipeline $9,340 19 payments
  3. WEB Aneurysm Embolization System Neurological Product $8,267 5 payments
  4. WEB $7,995 17 payments
  5. TREVO $2,424 29 payments
  6. SURPASS EVOLVE $2,299 55 payments
  7. TARGET $1,568 39 payments
  8. ECLIPSE 2L $1,480 2 payments
  9. Ballast 088 Long Sheath $1,480 2 payments
  10. Prestige Coil System $1,480 2 payments
  11. Other $9,586 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

26

Median for Neurosurgery: 83

Drug cost

$445

Median for Neurosurgery: $872

Branded share of claims

100%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 26 $445

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$12,656

Medicare's payments for the services billed

Medicare patients

16

Average age 75

Services billed

133

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Neurology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record